Their discovery may one day lead to new treatments for many common autoimmune diseases.
Researchers at the University of Georgia report in the Journal of Biological Chemistry that an enzyme known as Tumor Progression Locus 2, or Tpl2, plays a key role in directing and regulating several important components of the body’s immune system. Their discovery may one day lead to new treatments for many common autoimmune diseases.
“We know that immune dysfunction plays a serious role in a number of conditions, and we need better methods for controlling chronic inflammation,” said Wendy Watford, assistant professor of infectious diseases in UGA’s College of Veterinary Medicine and principal investigator for the study. “Our laboratory is searching for ways to disrupt the fundamental cellular processes that cause inflammation and disease.”
The human immune system is an extraordinarily complex system of cells, proteins, tissues and organs that, when everything works properly, search out and destroy disease-causing toxins and pathogens like bacteria and viruses. But sometimes it becomes confused, and the microscopic troops that normally attack only invaders turn their weapons on healthy tissues.
The resulting inflammation caused by wayward defense cells is associated with a number of autoimmune diseases and conditions, including diabetes, obesity, depression, heart disease, stroke, respiratory disease and certain cancers.
Read more . . .
The Latest on: Disease-causing inflammation
via Google News
The Latest on: Disease-causing inflammation
- Can Vitamin D protect you from COVID-19?on January 26, 2021 at 1:16 am
Not only is vitamin D important for bone and muscle health, but it plays a crucial role in the body's immune response. This has led scientists to question whether a daily dose of the sunshine supp ...
- Peninsula biotech pivots to kidney drug with $80M roundon January 19, 2021 at 10:45 am
Trucode Gene Repair with a focus on sickle cell disease and cystic fibrosis — said Tuesday that it will use its new Series C cash to boost manufacturing as it starts a mid-stage clinical trial with an ...
- Human body – the most misunderstood natural machineon January 19, 2021 at 12:49 am
Pathogenic (disease-causing) microorganisms must make it past this first ... Enhancement of phagocytosis (called Opsonization), stimulation of inflammation (called Chemotaxis), attracting macrophages ...
- BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Scienceon January 16, 2021 at 4:00 am
The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” summarizes the findings on the disease-suppressing effects of a non ...
- Rheumatoid arthritis symptoms: Two surprising signs of the joint conditionon January 15, 2021 at 6:53 am
RHEUMATOID arthritis is an auto-immune condition whereby the body's immune system mistakenly attacks healthy tissue. Inflammation results, which can lead to two surprising symptoms - what are they?
- Kymera Therapeutics (NASDAQ:KYMR) Lifted to “Hold” at Zacks Investment Researchon January 14, 2021 at 6:18 am
Zacks Investment Research upgraded shares of Kymera Therapeutics (NASDAQ:KYMR) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to ...
- Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a ...on January 12, 2021 at 10:56 pm
Strong financial position to support pipeline execution with opportunities to accelerate growth and broaden clinical indications WATERTOWN, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics ...
- AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for ...on January 12, 2021 at 10:54 pm
Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infections; COVID-19 GI infections are a significant unmet clinical need; AzurRx es ...
- Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Companyon January 12, 2021 at 2:31 pm
Initiation of the single ascending dose portion of Phase 1 trial of KT-474 in healthy volunteers anticipated in 1Q 2021 WATERTOWN, Mass., (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), ...
- Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Companyon January 11, 2021 at 11:00 pm
IRAK4 Degrader ProgramIRAK4 is a key protein involved in inflammation mediated by the ... platform to identify the optimal pairing of disease-causing protein targets with E3 ligases to generate ...
via Bing News
